Product Information
Registration Status: ActiveSIN03333P
COLIMIX SYRUP is approved to be sold in Singapore with effective from 1989-06-16. It is marketed by APEX PHARMA MARKETING PTE LTD, with the registration number of SIN03333P.
This product contains Dicyclomine 5mg/5ml, and Simethicone 50mg/5ml in the form of SYRUP. It is approved for ORAL use.
This product is manufactured by XEPA-SOUL PATTINSON (MALAYSIA) SDN BHD in MALAYSIA.
It is a Pharmacy Only Medicine that can be obtained from a pharmacist at a retail pharmacy.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
A muscarinic antagonist used as an antispasmodic and in urinary incontinence. It has little effect on glandular secretion or the cardiovascular system. It does have some local anesthetic properties and is used in gastrointestinal, biliary, and urinary tract spasms. [PubChem]
Indication
For the treatment of functional bowel/irritable bowel syndrome including Colicky abdominal pain; diverticulitis
Mechanism of Action
Action is achieved via a dual mechanism: (1) a specific anticholinergic effect (antimuscarinic) at the acetylcholine-receptor sites and (2) a direct effect upon smooth muscle (musculotropic).
Active Ingredient/Synonyms
2-(Diethylamino)ethyl 1-cyclohexylcyclohexanecarboxylate | Bicyclohexyl-1-carboxylic acid 2-diethylamino-ethyl ester | Dicicloverina | DICYCLOMINE | Dicycloverin | Dicycloverine | Dicycloverinum | Dicyclomine |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.
Description
Simethicone is an orally administered antifoaming agent. It is mainly used to reduce gas from the gastrointestinal tract (GIT) in patients complaining from recurrent flatulence. Simethicone is a mixture of polydimethylsiloxane and hydrated silica gel. It exerts its action locally in the GIT, it is not absorbed into the blood stream. The main side effects of simethicone are GIT related including: mild diarrhea, nausea and vomiting.
Indication
1. To relieve pain and discomfort caused by excess gas in the intestine and stomach in cases such as flatulence and post operative gaseous distention. 2. It could be used also prior to an endoscopy to eliminate foam, gas and air from the gastrointestinal tract to reduce gas shadow which will result in better visualization.
Mechanism of Action
Decreases the surface tension of gas bubbles thereby disperses and prevents gas pockets in the GI system.
Pharmacokinetics
- Absorption
- Not absorbed following oral administration.
- Distribution
- Simethicone is pharmacologically inert and is not absorbed from the gastrointestinal tract.
- Metabolism
- The drug is not absorbed and it is excreted in the feces unchanged.
- Elimination
Clearance
Excreted unchanged in feces.
Toxicity
LD50 (oral, rat): 4070 mg/Kg.
Active Ingredient/Synonyms
Simeticone | Simethicone |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.